We have read with great interest in Diabetes Care the results from the recent multicenter real-world prospective study conducted by Beato-Víbora et al. (1), comparing glucose and patient-reported outcomes 3 months after advanced hybrid closed-loop (AHCL) insulin delivery system initiation (either Medtronic SmartGuard 780G and Tandem T-Slim Control-IQ users). The authors concluded, based on continuous glucose monitoring from 150 participants (87% of whom are aged ≥25 years), that the AHCL systems provided significant and similar improvement in glucose control, partly in line with a recent publication from our group (2). Although we thank the authors for acknowledging our study, we believe a few clarifications need to be made regarding our cohort description and study design. First, our cohort consisted of 48 adolescents and 183 adults (contrary to the 75 participants mentioned in the article), with a median (95% CI) observation period of 283 (270.5–296) days. Throughout follow-ups, we found that 780G users had consistently better continuous glucose monitoring outcome improvements, including percent time in range (%TIR) (70–180 mg/dL), than Control-IQ users, while laboratory HbA1c improvements were similar between the two groups. We attributed these results to differences in algorithms, sensors, and/or amounts of automated insulin boluses between AHCL systems. In addition, we found that %TIR improvements remained lower in younger participants (
http://dlvr.it/T5lrMb
ليست هناك تعليقات:
إرسال تعليق
ملحوظة: يمكن لأعضاء المدونة فقط إرسال تعليق.